1. Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis

   • Joel P. Thompson
   • Amir Abdolahi
   • Katia Noyes

   Practical Application 03 May 2013 Pages: 455 - 469

   

2. Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal

   • Rachid Rafia
   • Emma Simpson
   • Diana Papaioannou

   Review Article 09 April 2013 Pages: 471 - 478

3. Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal

   • Ben Kearns
   • Myfanwy Lloyd Jones
   • Chris Littlewood

   Review Article 12 April 2013 Pages: 479 - 488

   

4. Disutility of Illness for Caregivers and Families: A Systematic Review of the Literature

   • Eve Wittenberg
   • Lisa A. Prosser

   Systematic Review 10 April 2013 Pages: 489 - 500

   

5. Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis

   • Fei-Li Zhao
   • Feng Xie
   • Shu-Chuen Li

   Systematic Review 26 April 2013 Pages: 501 - 508

   

6. Simulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes

   • Tom W. C. Lung
   • Philip M. Clarke
   • Andrew Farmer

   Original Research Article 13 April 2013 Pages: 509 - 518

   

7. Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome

   • Anju Parthan
   • Kevin J. Leahy
   • Milton C. Weinstein

   Original Research Article 13 April 2013 Pages: 519 - 531

   

8. A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’

   • Przemysław Holko
   • Paweł Kawalec

   CORRESPONDENCE Open access 29 March 2013 Pages: 533 - 535